NRIX (Nurix Therapeutics) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NRIX Nurix Therapeutics Inc NRIX
61 GF Score
Price $25.22
GF Value $6.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Nurix Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

NRIX
61GF Score
Nurix Therapeutics Inc NRIX
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nurix Therapeutics (NRIX) Overvalued in 2026?

Based on GuruFocus' analysis, Nurix Therapeutics stock appears to be overvalued. The current stock price of $25.22 is trading 294.1% above its estimated GF Value™ of $6.40. GuruFocus considers Nurix Therapeutics to be Significantly Overvalued.

Key valuation signals for NRIX:

  • Interest Expense (Positive):
  • GF Value™: $6.40 vs. price of $25.22 (294.1% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the NRIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nurix Therapeutics Business Description

Address 1600 Sierra Point Parkway, Brisbane, CA, USA, 94005
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
61GF Score

Get the complete analysis for NRIX

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.22
Price
$6.40
GF Value